NCT Number: NCT02526745
Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older
This study evaluates the safety and immunogenicity of live attenuated vaccine in adults aged 50 years and older. Half of participants will receive high doses of the vaccine,while the other half will receive low doses of the vaccine in phase I clinical trial. At the phase II clinical trial, participants will be distributed equally to four groups(low、middle, high doses of the vaccine and placebo).
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1 / Phase 2
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Adults 50 years and older,no vaccine contraindications;
- Subject to comply with the requirements of clinical trial programs;
- No immune globulin vaccination history within a month, no vaccination history within 28 days;
- Axillary temperature ≤37.0 ℃;
- Patients with chronic diseases should be in stable ;
- Postmenopausal or female subjects is no longer the possibility of pregnancy, or subjects pregnancy test was negative and has no pregnancy planner during the clinical trial period;
- The value of blood routine (WBC, RBC, Hb) is normal , or abnormal but meaningless by clinicians judgment ;
- Alanine aminotransferase (ALT) values is normal, or abnormal but meaningless by clinicians judgment ;
- Renal function (serum urea nitrogen) is normal, or abnormal but meaningless by clinicians judgment.
Exclusion criteria
- Allergies, seizures, epilepsy, encephalopathy and other medical history or family history of mental illness;
- Subjects who is allergic to any element of the vaccine,and have a history of severe allergy to any vaccine;
- Subjects who is suffering from immune deficiency, receiving immunosuppressive therapy or immunocompromised due to HIV;
- Subjects who had a history of herpes zoster five years ago;
- Varicella or herpes zoster vaccination history;
- Pregnant or lactating women;
- Women who are planning a pregnancy in the near future;
- Any prior administration of vaccine in last 28 days or planned to vaccinate any vaccine during the observation period;
- Suffering from acute febrile diseases, and infectious diseases;
- Thrombocytopenia or other coagulation disorder history, which may cause subcutaneous taboo;
- Accept any other investigational drug users within two months;
- Subjects had high fever (axillary temperature ≥38.0 ℃) in the past three days ;
- The value of blood routine (WBC, RBC, Hb) is abnormal and meaning by clinicians judgment ;
- Alanine aminotransferase (ALT) values is abnormal and meaning by clinicians judgment ;
- Renal function (serum urea nitrogen) is abnormal and meaning by clinicians judgment.
- Blood pressure is abnormal after medication control;
- Known or suspected diseases including: respiratory diseases, acute infection or chronic disease , and cardiovascular disease, kidney disease, skin disorders in the acute phase;
- Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.
Treatment and study plan
the vaccine with low doses of virus content between 4.7~5.0 lgPFU
Biologicalthe vaccine with high doses of virus content between 4.3~5.0 lgPFU
Biologicalthe vaccine with middle doses of virus content between 4.3~5.0 lgPFU
Biologicalthe vaccine with low doses of virus content between 4.3~5.0 lgPFU
BiologicalPlacebo
BiologicalPrimary outcomes
-
Evaluate the Rate of Adverse reactions of live attenuated Herpes zoster Vaccine in Chinese Adults.
Time frame: 42 days
Adverse reactions associated with vaccine will be observed in Chinese Adults ( 50 years and older) after vaccination. Solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diarrhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
Secondary outcomes
-
Evaluate the seroconversion rate of anti-herpes zoster virus antibodies in serum of adults after vaccination.
Time frame: 6 months
The seroconversion rate of anti-herpes zoster virus antibodies will be evaluated in serum of adults within the first 42 days after vaccination.
Sponsors and collaborators
Lead sponsor
Beijing Chaoyang District Centre for Disease Control and Prevention
Other
Registry information
Important dates
- Study start
- 2015
- Primary completion
- 2016
- First posted
- Aug 18, 2015
- Registry last updated
- Aug 15, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical and Economic Impact of Herpes Zoster in Cancer Patients
NCT06207487
DNA Virus Infections, Herpes Zoster
São Paulo, Brazil
View Trial DetailsThe Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
NCT03604406
Arthritis, Arthritis, Rheumatoid
Boise, Idaho, United States
View Trial DetailsA Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT06375512
Chickenpox, DNA Virus Infections
Hollywood, Florida, United States
View Trial DetailsPostherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk
NCT07399288
Alzheimer Disease, Arterial Occlusive Diseases
Taichung, Taichung City, Taiwan
View Trial Details